<DOC>
	<DOCNO>NCT02017912</DOCNO>
	<brief_summary>This multi-center , randomize , double blind , placebo control study evaluate safety efficacy autologous ( self ) transplantation Neurotrophic factors-secreting Mesenchymal Stromal Cells ( MSC-NTF , NurOwn™ ) patient ALS . MSC-NTF cell novel cell-therapeutic approach expect effectively deliver Neurotrophic factor , potent survival factor neuron , directly site damage .</brief_summary>
	<brief_title>Phase 2 , Randomized , Double Blind , Placebo Controlled Multicenter Study Autologous MSC-NTF Cells Patients With ALS</brief_title>
	<detailed_description>The MSC-NTF cell therapy ( NurOwn™ ) base transplantation autologous bone marrow derive mesenchymal stromal cell ( MSC ) , enrich patient ' bone marrow , propagate ex vivo induce secrete NTFs . The autologous MSC-NTF cell back-transplanted ALS patient sit damage , spinal cord muscle . NTFs potent survival factor embryonic , neonatal , adult neuron consider potential therapeutic candidate ALS . Delivery appropriate NTFs immediate environment afflict neuron ALS patient expect improve survival thus slow disease progression alleviate symptom . Previous open-label clinical trial show MSC-NTF cell treatment well tolerated appear generally safe . Some initial indication clinical benefit also observe patient . This multi-center , randomize , double blind , placebo control study evaluate safety efficacy single combine intramuscular intrathecal administration MSC-NTF cell early-stage ALS patient . Patients follow approximately three month transplantation autologous MSC-NTF cell placebo . During period time , patient bone-marrow harvest mesenchymal stromal cell isolate expand . Following treatment patient follow total six month monthly visit .</detailed_description>
	<mesh_term>Motor Neuron Disease</mesh_term>
	<mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
	<criteria>Inclusion Criteria 1 . Males female age 18 75 year old , inclusive . 2 . ALS diagnose possible , laboratorysupported probable , probable , definite define revise El Escorial criterion . 3 . Disease onset , define first report occurrence symptomatic weakness , spasticity , bulbar symptom , 12 month less equal 24 month . 4 . Current disease symptom must include limb weakness . 5 . ALSFRSR ≥30 Screening Visit . 6 . Upright slow vital capacity ( SVC ) measure ≥65 % predict gender , height , age Screening Visit . 7 . Subjects must take stable dose riluzole least 30 day prior enrolment riluzole , least 30 day prior enrolment ( riluzolenaïve subject permit study ) . 8 . Capable provide informed consent willing able follow study procedure , include willingness undergo lumbar puncture . 9 . Geographic accessibility study site willingness ability comply followup . 10 . Women childbearing potential must agree become pregnant duration study . Women must willing consistently use two form contraceptive therapy throughout course trial , undergo pregnancy test one week bone marrow aspiration . Men must willing consistently use two form contraceptive partner childbearing age . 11 . Citizen permanent resident United States . 1 . Prior stem cell therapy kind . 2 . Inability lie flat duration intrathecal cell transplantation and/or bone marrow biopsy , inability tolerate study procedure reason . 3 . History autoimmune disease ( exclude thyroid disease ) myelodysplastic myeloproliferative disorder , leukemia lymphoma , whole body irradiation , hip fracture , severe scoliosis . 4 . Any unstable clinically significant medical condition ALS ( e.g. , within six month baseline , myocardial infarction , angina pectoris , and/or congestive heart failure ) , treatment anticoagulant , opinion investigator , would compromise safety patient . 5 . Any history malignancy include malignancy affect central nervous system melanoma , within previous 5 year , exception localize skin cancer ( evidence metastasis , significant invasion , reoccurrence within three year baseline ) . 6 . Serum AST ALT value &gt; 3.0 time upper normal limit . 7 . Serum creatinine value &gt; 2.0 time upper normal limit . 8 . Positive test Hepatitis B , Hepatitis C , HIV . 9 . Current use immunosuppressant medication use medication within 4 week Screening visit ( Visit 1 ) . 10 . Any history acquire inherit immune deficiency syndrome . 11 . Exposure experimental agent ( offlabel use investigational ) participation clinical trial within 30 day prior Screening Visit ( Visit 1 ) . 12 . Use noninvasive ventilation ( NIV ) , diaphragm pace system invasive ventilation ( tracheostomy ) . 13 . Any history either substance abuse within past year , unstable psychiatric disease accord PI judgment . 14 . Placement usage feed tube . 15 . Pregnant woman woman currently breastfeed .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Mesenchymal Stromal cell</keyword>
	<keyword>MSC-NTF</keyword>
	<keyword>Cell therapy</keyword>
	<keyword>ALS</keyword>
</DOC>